


Amendments to the Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

1. (Currently Amended) A compound comprising of a formula:




or a pharmaceutically acceptable salt or a prodrug or a metabolite thereof; wherein Y is $\text{CO}_2(\text{R}^2)$, $\text{CON}(\text{R}^2)_2$, $\text{CON}(\text{OR}^2)\text{R}^2$, $\text{CON}(\text{CH}_2\text{CH}_2\text{OH})_2$, $\text{CONH}(\text{CH}_2\text{CH}_2\text{OH})$, CH_2OH , $\text{P}(\text{O})(\text{OH})_2$, $\text{CONHSO}_2\text{R}^2$, $\text{SO}_2\text{N}(\text{R}^2)_2$, SO_2NHR^2 , or tetrazolyl- R^2 ; wherein each R^2 is independently H, $\text{C}_1\text{-C}_6$ alkyl, phenyl, or biphenyl an organic acid functional group, or an amide or ester thereof comprising up to 12 carbon atoms; or Y is hydroxymethyl or an ether thereof comprising up to 12 carbon atoms; or Y is a tetrazolyl functional group; A is $-(\text{CH}_2)_6-$, *cis* $-\text{CH}_2\text{CH}=\text{CH}-(\text{CH}_2)_3-$, or $-\text{CH}_2\text{C}\equiv\text{C}-(\text{CH}_2)_3-$, wherein 1 or 2 carbon atoms may be substituted replaced with S or O; or A is $-(\text{CH}_2)_m\text{-Ar-}(\text{CH}_2)_o-$ wherein Ar is interarylene or heterointerarylene, the sum of m and o is from 1 to 4, and wherein one CH_2 may be substituted replaced with S or O; and D is aryl or heteroaryl.

2. (Original) The compound of claim 1 wherein D is phenyl.

3. (Original) The compound of claim 2 wherein D is chlorophenyl.


4. (Original) The compound of claim 3 wherein D is 3,5-dichlorophenyl.

5. (Original) The compound of claim 2 wherein D is unsubstituted phenyl.
6. (Original) The compound according to any one of claims 1 to 5, wherein A is $-(CH_2)_6-$, *cis* $-CH_2CH=CH-(CH_2)_3-$, or $-CH_2O\equiv C-(CH_2)_3-$.
7. (Currently Amended) The compound of claim 2 comprising further represented by a formula:




or a pharmaceutically acceptable salt or a prodrug or a metabolite thereof;
wherein R³ is independently methyl, ethyl, isopropyl, fluoro, chloro, bromo, methoxy,
ethoxy, isopropoxy, NH₂, OH, CN, NO₂, or CF₃; and
n is 0, 1, 2, or 3.

8. (Currently Amended) The compound of claim 7 comprising further represented by a formula:




or a pharmaceutically acceptable salt or a prodrug or a metabolite thereof;
wherein a dashed line indicates the presence or absence of a covalent bond.

9. (Currently Amended) The compound of claim 2 comprising



or a pharmaceutically acceptable salt or a prodrug or a metabolite thereof;
wherein R³ is independently methyl, ethyl, isopropyl, fluoro, chloro, bromo, methoxy, ethoxy, isopropoxy, NH₂, OH, CN, NO₂, or CF₃;
R⁴ is hydroxyhydrocarbyl having from 1 to 10 carbon atoms; and
n is 0, 1, 2, or 3.


10. (Currently Amended) A method comprising administering an effective amount of a compound to a mammal for the treatment or prevention of glaucoma or ocular hypertension, said compound comprising represented by a formula:



or a pharmaceutically acceptable salt or a prodrug or a metabolite thereof;
wherein Y is CO₂(R²), CON(R²)₂, CON(OR²)R², CON(CH₂CH₂OH)₂, CONH(CH₂CH₂OH), CH₂OH, P(O)(OH)₂, CONHSO₂R², SO₂N(R²)₂, SO₂NHR², or tetrazolyl-R²; wherein each R² is independently H, C₁-C₆ alkyl, phenyl, or biphenyl an organic acid functional group, or an amide or ester thereof comprising up to 12 carbon atoms; or Y is hydroxymethyl or an ether thereof comprising up to 12 carbon atoms; or Y is a tetrazolyl functional group;
A is -(CH₂)₆-, cis -CH₂CH=CH-(CH₂)₃-, or -CH₂C≡C-(CH₂)₃-, wherein 1 or 2 carbon atoms may be substituted replaced with S or O; or A is -(CH₂)_m-Ar-(CH₂)₀- wherein Ar is

interarylene or heterointerarylene, the sum of m and o is from 1 to 4, and wherein one CH₂ may be substituted replaced with S or O; and D is aryl or heteroaryl.

11. (Currently Amended) A liquid comprising a compound and a liquid carrier, wherein said liquid is ophthalmically acceptable, said compound comprising represented by a formula:



or a pharmaceutically acceptable salt or a prodrug or a metabolite thereof; wherein Y is CO₂(R²), CON(R²)₂, CON(OR²)R², CON(CH₂CH₂OH)₂, CONH(CH₂CH₂OH), CH₂OH, P(O)(OH)₂, CONHSO₂R², SO₂N(R²)₂, SO₂NHR², or tetrazolyl-R²; wherein each R² is independently H, C₁-C₆ alkyl, phenyl, or biphenyl an organic acid functional group, or an amide or ester thereof comprising up to 12 carbon atoms; or Y is hydroxymethyl or an ether thereof comprising up to 12 carbon atoms; or Y is a tetrazolyl functional group; A is -(CH₂)₆-, cis -CH₂CH=CH-(CH₂)₃-, or -CH₂C≡C-(CH₂)₃-, wherein 1 or 2 carbon atoms may be substituted replaced with S or O; or A is -(CH₂)_m-Ar-(CH₂)_o- wherein Ar is interarylene or heterointerarylene, the sum of m and o is from 1 to 4, and wherein one CH₂ may be substituted replaced with S or O; and D is aryl or heteroaryl.

12. (Cancelled)

13. (New) The method of claim 10, wherein D is phenyl.

14. (New) The method of claim 13 wherein D is 3,5-dichlorophenyl.

15. (New) The method of claim 13, wherein Ar is interphenylene, interthienylene, interfurylene, interoxazolylene, or interthiazolylene.
16. (New) The method of claim 15, wherein Ar is unsubstituted, or all substituents present on Ar are independently C₁₋₄ alkyl, CF₃, F, Cl, Br, OH, and NH₂.
17. (New) The liquid of claim 11, wherein Y is CO₂(R²) or CON(R²)₂.
18. (New) The liquid of claim 17, wherein D is phenyl.
19. (New) The liquid of claim 11, wherein Ar is interthienylene.
20. (New) The liquid of claim 19, wherein D is phenyl.
21. (New) The liquid of claim 20, wherein Ar is interthienylene and Y is CO₂(R²).